Marie Winther-Sørensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marie Winther-Sørensen has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Nicolai Jacob Wewer Albrechtsen
Department of Clinical Biochemistry Copenhagen University Hospital – Bispebjerg and Frederiksberg Copenhagen Denmark
22 shared publications - Jens Juul Holst
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
18 shared publications - Katrine Douglas Galsgaard
Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
9 shared publications - Sasha Alexandra Sampson Kjeldsen
Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital , Copenhagen
8 shared publications - Filip Krag Knop
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
6 shared publications Jens Pedersen
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
6 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
Exogenous Glucagon Acutely Reduces Insulin Clearance in Healthy Humans
Context: Glucagon is secreted from pancreatic alpha-cells in response to hypoglycemia and protein intake and acts as a counterregulatory hormone to insulin by stimulating hepatic glucose production, thereby maintaining euglycemia. However, some studies suggest that glucagon regulates insulin availability by stimulating insulin secretion and reducing insulin clearance. Objective: To investigate the glucose-independent effect of glucagon on insulin secretion and insulin clearance in healthy individuals. Methods: A total of 15 healthy participants were included in this single arm, crossover clinical study with two study days. The participants received a four-hour intravenous infusion of glucagon (10 ng × kg(bodyweight)-1×min-1) on the first study day and a four-hour intravenous infusion of glucose (to match the glucose excursions from the glucagon infusion) on the second study day. The primary endpoint was insulin secretion (c-peptide). Results: Overall glucose exposure did not differ significantly between study days (P = 0.0717); however, peak plasma glucose was significantly higher on the glucose clamp day (8.1 (7.5-8.7) vs 7.7 (7.0-8.3) mmol/L, P = 0.0027), reflecting incomplete glucose matching. Steady state concentrations of glucagon were 124 (110-137) pmol/L on the glucagon study day and 3 (2-4) pmol/L on the glucose clamp study day. There was no statistically significant difference in insulin secretion between study days (P = 0.1179), whereas insulin clearance (post hoc analysis) was significantly reduced during glucagon infusion at both hyper- and euglycemia (P = 0.0003). Conclusions: Exogenous glucagon rapidly reduces insulin clearance without a statistically significant effect on insulin secretion, suggesting that glucagon affects hepatic insulin removal in healthy individuals.
- 31 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
Open AccessExogenous Glucagon Acutely Reduces Insulin Clearance in Healthy Humans
Context: Glucagon is secreted from pancreatic alpha-cells in response to hypoglycemia and protein intake and acts as a counterregulatory hormone to insulin by stimulating hepatic glucose production, thereby maintaining euglycemia. However, some studies suggest that glucagon regulates insulin availability by stimulating insulin secretion and reducing insulin clearance. Objective: To investigate the glucose-independent effect of glucagon on insulin secretion and insulin clearance in healthy individuals. Methods: A total of 15 healthy participants were included in this single arm, crossover clinical study with two study days. The participants received a four-hour intravenous infusion of glucagon (10 ng × kg(bodyweight)-1×min-1) on the first study day and a four-hour intravenous infusion of glucose (to match the glucose excursions from the glucagon infusion) on the second study day. The primary endpoint was insulin secretion (c-peptide). Results: Overall glucose exposure did not differ significantly between study days (P = 0.0717); however, peak plasma glucose was significantly higher on the glucose clamp day (8.1 (7.5-8.7) vs 7.7 (7.0-8.3) mmol/L, P = 0.0027), reflecting incomplete glucose matching. Steady state concentrations of glucagon were 124 (110-137) pmol/L on the glucagon study day and 3 (2-4) pmol/L on the glucose clamp study day. There was no statistically significant difference in insulin secretion between study days (P = 0.1179), whereas insulin clearance (post hoc analysis) was significantly reduced during glucagon infusion at both hyper- and euglycemia (P = 0.0003). Conclusions: Exogenous glucagon rapidly reduces insulin clearance without a statistically significant effect on insulin secretion, suggesting that glucagon affects hepatic insulin removal in healthy individuals.
- Open Access
- 1 October 2026
- Published by Springer Nature in Communications Medicine
Proteomic profiling of liver and plasma uncovers biomarkers and mechanisms in patients with primary biliary cholangitis
- 1 October 2026
- Published by Springer Nature in Communications Medicine
Open AccessProteomic profiling of liver and plasma uncovers biomarkers and mechanisms in patients with primary biliary cholangitis
- Open Access
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F542-F551
Acute glucagon infusion induces natriuresis and diuresis through a direct tubular mechanism involving overlapping receptor pathways
Glucagon is best known for raising blood sugar, but what does it do to the kidneys? We show that glucagon consistently drives sodium and water excretion in rats through a direct tubular mechanism, largely independent of changes in renal blood flow. Neither glucagon receptor nor GLP-1 receptor blockade alone was sufficient to abolish the response, revealing overlapping receptor pathways. These findings have implications for the growing use of glucagon-based dual and triple agonist therapies.
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 331 (4) , F542-F551
Open AccessAcute glucagon infusion induces natriuresis and diuresis through a direct tubular mechanism involving overlapping receptor pathways
Glucagon is best known for raising blood sugar, but what does it do to the kidneys? We show that glucagon consistently drives sodium and water excretion in rats through a direct tubular mechanism, largely independent of changes in renal blood flow. Neither glucagon receptor nor GLP-1 receptor blockade alone was sufficient to abolish the response, revealing overlapping receptor pathways. These findings have implications for the growing use of glucagon-based dual and triple agonist therapies.
- 12 June 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (14) , 5926-5935
Amino acids partially override inhibitory effects of octreotide on islet hormone secretion in healthy individuals
Hyperaminoacidaemia and hyperglucagonaemia are hallmarks of metabolic dysfunction–associated liver disease and type 2 diabetes. Amino acids potently stimulate glucagon secretion and can stimulate insulin secretion, although less potently than glucose. Endogenous somatostatin released from pancreatic δ‐cells inhibits islet hormone output. It remains uncertain whether amino acid–induced stimulation can dominate pharmacological somatostatin receptor (SSTR) activation in humans. To address this we examined hormonal responses to intravenous amino acid infusion (Vamin) with and without concomitant infusion of the somatostatin analogue octreotide in 15 healthy individuals. Plasma glucagon, insulin and C‐Peptide were measured during 45 min of amino acid infusion alone, during amino acid infusion combined with a 240‑min octreotide infusion and during octreotide infusion without amino acids. Octreotide alone suppressed glucagon and insulin concentrations by greater than 90% and reduced C‑Peptide by greater than 65%. In contrast amino acids alone significantly increased all three peptides. When amino acids and octreotide were co‑infused, the amino acid–driven elevations in glucagon, insulin and C‑Peptide were reduced to 49%, 43% and 78% of the levels achieved by amino acids alone. These findings demonstrate robust α‑ and β‑cell secretion during SSTR‐2‑biased agonism despite profound baseline suppression, indicating partial ‘breakthrough’ secretion and suggesting that amino acid–driven stimulation can, in part, counteract SSTR‑mediated inhibition in humans. image Key points: Amino acids strongly stimulate glucagon secretion in humans, whereas somatostatin receptor (SSTR) activation potently inhibits basal islet hormone release. During near‐maximal suppression with the somatostatin analogue octreotide, amino acid infusion induced substantial ‘breakthrough’ secretion of glucagon, insulin and C‐Peptide. Co‐infusion of amino acids and octreotide reduced amino acid–stimulated responses to 49% (glucagon), 47% (insulin) and 78% (C‐Peptide) of amino acids alone. Breakthrough secretion was not specific to α‐cells, indicating that strong secretagogue stimulation can partially escape somatostatin‐mediated inhibition for both α‐ and β‐cells. These in vivo human data support a balance‐of‐signals model in which elevated amino acids can counteract, but not fully overcome, inhibitory SSTR activation. Highlights: We performed this study to determine why hyperglucagonaemia persists in metabolic diseases despite somatostatin's inhibitory role. We specifically evaluated whether amino acid–induced glucagon secretion can persist during pharmacological somatostatin receptor (SSTR) activation (octreotide) in humans. We found that amino acids strongly stimulated glucagon, insulin and C‐Peptide secretion even during somatostatin infusion, reducing but not eliminating the hormonal responses. These findings imply that amino acid–driven stimulation can partially bypass inhibitory signalling downstream of SSTR activation, helping explain persistent glucagon elevation in metabolic disorders.
- 12 June 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (14) , 5926-5935
Amino acids partially override inhibitory effects of octreotide on islet hormone secretion in healthy individuals
Hyperaminoacidaemia and hyperglucagonaemia are hallmarks of metabolic dysfunction–associated liver disease and type 2 diabetes. Amino acids potently stimulate glucagon secretion and can stimulate insulin secretion, although less potently than glucose. Endogenous somatostatin released from pancreatic δ‐cells inhibits islet hormone output. It remains uncertain whether amino acid–induced stimulation can dominate pharmacological somatostatin receptor (SSTR) activation in humans. To address this we examined hormonal responses to intravenous amino acid infusion (Vamin) with and without concomitant infusion of the somatostatin analogue octreotide in 15 healthy individuals. Plasma glucagon, insulin and C‐Peptide were measured during 45 min of amino acid infusion alone, during amino acid infusion combined with a 240‑min octreotide infusion and during octreotide infusion without amino acids. Octreotide alone suppressed glucagon and insulin concentrations by greater than 90% and reduced C‑Peptide by greater than 65%. In contrast amino acids alone significantly increased all three peptides. When amino acids and octreotide were co‑infused, the amino acid–driven elevations in glucagon, insulin and C‑Peptide were reduced to 49%, 43% and 78% of the levels achieved by amino acids alone. These findings demonstrate robust α‑ and β‑cell secretion during SSTR‐2‑biased agonism despite profound baseline suppression, indicating partial ‘breakthrough’ secretion and suggesting that amino acid–driven stimulation can, in part, counteract SSTR‑mediated inhibition in humans. image Key points: Amino acids strongly stimulate glucagon secretion in humans, whereas somatostatin receptor (SSTR) activation potently inhibits basal islet hormone release. During near‐maximal suppression with the somatostatin analogue octreotide, amino acid infusion induced substantial ‘breakthrough’ secretion of glucagon, insulin and C‐Peptide. Co‐infusion of amino acids and octreotide reduced amino acid–stimulated responses to 49% (glucagon), 47% (insulin) and 78% (C‐Peptide) of amino acids alone. Breakthrough secretion was not specific to α‐cells, indicating that strong secretagogue stimulation can partially escape somatostatin‐mediated inhibition for both α‐ and β‐cells. These in vivo human data support a balance‐of‐signals model in which elevated amino acids can counteract, but not fully overcome, inhibitory SSTR activation. Highlights: We performed this study to determine why hyperglucagonaemia persists in metabolic diseases despite somatostatin's inhibitory role. We specifically evaluated whether amino acid–induced glucagon secretion can persist during pharmacological somatostatin receptor (SSTR) activation (octreotide) in humans. We found that amino acids strongly stimulated glucagon, insulin and C‐Peptide secretion even during somatostatin infusion, reducing but not eliminating the hormonal responses. These findings imply that amino acid–driven stimulation can partially bypass inhibitory signalling downstream of SSTR activation, helping explain persistent glucagon elevation in metabolic disorders.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 330 (4) , E510-E519
Glucagon may be extracted across the liver by a glucagon receptor-dependent mechanism, and this is impaired in an animal model of fatty liver disease
We identify the liver as an active glucagon‐clearing organ: ∼20% of portal glucagon is extracted under physiological conditions via glucagon receptor-dependent uptake, not enzymatic cleavage. DPP-4 and neprilysin inhibition does not alter hepatic glucagon disappearance, and mass spectrometry confirms glucagon remains largely intact. Strikingly, diet-induced hepatic steatosis nearly abolishes glucagon extraction, coinciding with reduced hepatic GCGR expression, suggesting impaired receptor-mediated clearance may contribute to hyperglucagonemia in MASLD.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 330 (4) , E510-E519
Glucagon may be extracted across the liver by a glucagon receptor-dependent mechanism, and this is impaired in an animal model of fatty liver disease
We identify the liver as an active glucagon‐clearing organ: ∼20% of portal glucagon is extracted under physiological conditions via glucagon receptor-dependent uptake, not enzymatic cleavage. DPP-4 and neprilysin inhibition does not alter hepatic glucagon disappearance, and mass spectrometry confirms glucagon remains largely intact. Strikingly, diet-induced hepatic steatosis nearly abolishes glucagon extraction, coinciding with reduced hepatic GCGR expression, suggesting impaired receptor-mediated clearance may contribute to hyperglucagonemia in MASLD.
- 1 November 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (5) , E581-E590
Glucagon increases plasma levels of cyclic AMP responses in mice and humans, and this may be independent of MASLD
Here, we investigate the molecular cause for hepatic glucagon resistance in MASLD. We demonstrate that cAMP responses to glucagon are preserved in both humans and mice with liver steatosis, suggesting that the defect lies downstream of cAMP production. These findings redefine the understanding of glucagon resistance and point toward alternative mechanisms beyond second messenger activation.
- 1 November 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 329 (5) , E581-E590
Glucagon increases plasma levels of cyclic AMP responses in mice and humans, and this may be independent of MASLD
Here, we investigate the molecular cause for hepatic glucagon resistance in MASLD. We demonstrate that cAMP responses to glucagon are preserved in both humans and mice with liver steatosis, suggesting that the defect lies downstream of cAMP production. These findings redefine the understanding of glucagon resistance and point toward alternative mechanisms beyond second messenger activation.
- Open Access
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (5) , F712-F724
Glucagon receptor activation contributes to the development of kidney injury
This study suggests that the glucagon receptor is a potential therapeutic target in the treatment of diabetic kidney disease. We show, in mice, that long-term treatment with a glucagon analog showed not only pathophysiological changes and changes in renal function but also transcriptional changes in the kidneys, whereas opposite effects were demonstrated in mice with glucagon receptor inactivation. Therefore, the use of glucagon in a treatment regimen requires investigation of possible metabolic and renal abnormalities.
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (5) , F712-F724
Open AccessGlucagon receptor activation contributes to the development of kidney injury
This study suggests that the glucagon receptor is a potential therapeutic target in the treatment of diabetic kidney disease. We show, in mice, that long-term treatment with a glucagon analog showed not only pathophysiological changes and changes in renal function but also transcriptional changes in the kidneys, whereas opposite effects were demonstrated in mice with glucagon receptor inactivation. Therefore, the use of glucagon in a treatment regimen requires investigation of possible metabolic and renal abnormalities.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 327 (4) , G558-G570
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease
Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) present with increased plasma levels of glucagon (hyperglucagonemia), irrespective of body mass index (BMI) and type 2 diabetes. Therefore, MASLD and the resultant hyperglucagonemia may act as a diabetogenic risk factor. Notably, hepatic steatosis was a significant contributor to the hyperglucagonemia in MASLD, potentially unveiling a pathway for the hyperglucagonemia in some patients with type 2 diabetes.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 327 (4) , G558-G570
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease
Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) present with increased plasma levels of glucagon (hyperglucagonemia), irrespective of body mass index (BMI) and type 2 diabetes. Therefore, MASLD and the resultant hyperglucagonemia may act as a diabetogenic risk factor. Notably, hepatic steatosis was a significant contributor to the hyperglucagonemia in MASLD, potentially unveiling a pathway for the hyperglucagonemia in some patients with type 2 diabetes.
- Open Access
- 6 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (8) , 1602-1615
Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study
Aims/hypotheses: Glucagon and glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon, and dual agonists of their receptors are currently being explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and MASLD. GLP-1 levels have been reported to be largely unaffected or even reduced in similar conditions. We investigated potential determinants of plasma proglucagon and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ~410,000 white participants to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Data on plasma levels of proglucagon estimated using Olink technology were available for a subset of the cohort (~40,000). We determined associations of glucagon receptor variants and proglucagon with BMI, type 2 diabetes and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated proglucagon predicts type 2 diabetes development. Results: Obesity, MASLD and type 2 diabetes were associated with elevated plasma levels of proglucagon independently of each other. Baseline proglucagon levels were associated with the risk of type 2 diabetes development over a 14 year follow-up period (HR 1.13; 95% CI 1.09, 1.17; n=1562; p=1.3×10−12). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of proglucagon (β 0.847; 95% CI 0.04, 1.66; n=17; p=0.04), and carriers of variants with a predicted frameshift mutation had higher levels of liver fat compared with the wild-type reference group (β 0.504; 95% CI 0.03, 0.98; n=11; p=0.04). Conclusions/interpretation: Our findings support the suggestion that glucagon receptor signalling is involved in MASLD, that plasma levels of proglucagon are linked to the risk of type 2 diabetes development, and that proglucagon levels are influenced by genetic variation in the glucagon receptor, obesity, type 2 diabetes and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Data availability: All coding is available through https://github.com/nicwin98/UK-Biobank-GCG Graphical
- 6 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (8) , 1602-1615
Open AccessDeterminants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study
Aims/hypotheses: Glucagon and glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon, and dual agonists of their receptors are currently being explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and MASLD. GLP-1 levels have been reported to be largely unaffected or even reduced in similar conditions. We investigated potential determinants of plasma proglucagon and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ~410,000 white participants to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Data on plasma levels of proglucagon estimated using Olink technology were available for a subset of the cohort (~40,000). We determined associations of glucagon receptor variants and proglucagon with BMI, type 2 diabetes and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated proglucagon predicts type 2 diabetes development. Results: Obesity, MASLD and type 2 diabetes were associated with elevated plasma levels of proglucagon independently of each other. Baseline proglucagon levels were associated with the risk of type 2 diabetes development over a 14 year follow-up period (HR 1.13; 95% CI 1.09, 1.17; n=1562; p=1.3×10−12). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of proglucagon (β 0.847; 95% CI 0.04, 1.66; n=17; p=0.04), and carriers of variants with a predicted frameshift mutation had higher levels of liver fat compared with the wild-type reference group (β 0.504; 95% CI 0.03, 0.98; n=11; p=0.04). Conclusions/interpretation: Our findings support the suggestion that glucagon receptor signalling is involved in MASLD, that plasma levels of proglucagon are linked to the risk of type 2 diabetes development, and that proglucagon levels are influenced by genetic variation in the glucagon receptor, obesity, type 2 diabetes and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Data availability: All coding is available through https://github.com/nicwin98/UK-Biobank-GCG Graphical
- Open Access
Determinants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank study
Aims/hypotheses: Glucagon and Glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon (gcg), and dual agonists of their receptors are currently explored for the treatment of obesity and steatotic liver disease. Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). It is unknown whether type 2 diabetes, obesity or MASLD causes hyperglucagonaemia or vice versa. We investigated potential determinants of plasma gcg and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ∼410,000 Caucasians to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Plasma levels of gcg estimated using Olink technology was available for a subset of the cohort (∼40,000). We determined associations between glucagon receptor variants and gcg with BMI, type 2 diabetes, and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated gcg predicts type 2 diabetes development. Results: Obesity, MASLD, and type 2 diabetes independently associated with elevated plasma levels of gcg. Baseline gcg levels were statistically significantly associated with the risk of type 2 diabetes development over a 14-year follow-up period (hazard ratio = 1.13; 95% confidence interval (CI) = 1.09, 1.17, p < 0.0001). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of gcg (β = 0.847; CI = 0.04, 1.66; p = 0.04), and carriers of variants with a predicted frameshift mutation had significantly higher levels of liver fat compared to wild-type controls (β = 0.504; CI = 0.03, 0.98; p = 0.04). Conclusions/interpretation: Our findings support that glucagon receptor signalling is involved in MASLD and type 2 diabetes, and that plasma levels of gcg are determined by genetic variation in the glucagon receptor, obesity, type 2 diabetes, and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Research in context: What is already known about this subject? Glucagon contributes to fasting hyperglycaemia in type 2 diabetes Hyperglucagonemia is often observed in metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and type 2 diabetes Glucagon/GLP-1 co-agonists have superior metabolic benefits compared to monoagonists What is the key question? What are key determinants of plasma proglucagon (gcg) and is elevated plasma gcg a cause or consequence (or both) of type 2 diabetes? What are the new findings? Plasma levels of gcg are increased in type 2 diabetes, MASLD and obesity independently of each other Increased plasma gcg associates with higher risk of type 2 diabetes development Glucagon signalling associates with hepatic fat How might this impact on clinical practice in the foreseeable future? Biased glucagon receptor-regulating agents may be beneficial in the treatment of obesity and MASLD.
Open AccessDeterminants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank study
Aims/hypotheses: Glucagon and Glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon (gcg), and dual agonists of their receptors are currently explored for the treatment of obesity and steatotic liver disease. Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). It is unknown whether type 2 diabetes, obesity or MASLD causes hyperglucagonaemia or vice versa. We investigated potential determinants of plasma gcg and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ∼410,000 Caucasians to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Plasma levels of gcg estimated using Olink technology was available for a subset of the cohort (∼40,000). We determined associations between glucagon receptor variants and gcg with BMI, type 2 diabetes, and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated gcg predicts type 2 diabetes development. Results: Obesity, MASLD, and type 2 diabetes independently associated with elevated plasma levels of gcg. Baseline gcg levels were statistically significantly associated with the risk of type 2 diabetes development over a 14-year follow-up period (hazard ratio = 1.13; 95% confidence interval (CI) = 1.09, 1.17, p < 0.0001). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of gcg (β = 0.847; CI = 0.04, 1.66; p = 0.04), and carriers of variants with a predicted frameshift mutation had significantly higher levels of liver fat compared to wild-type controls (β = 0.504; CI = 0.03, 0.98; p = 0.04). Conclusions/interpretation: Our findings support that glucagon receptor signalling is involved in MASLD and type 2 diabetes, and that plasma levels of gcg are determined by genetic variation in the glucagon receptor, obesity, type 2 diabetes, and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Research in context: What is already known about this subject? Glucagon contributes to fasting hyperglycaemia in type 2 diabetes Hyperglucagonemia is often observed in metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and type 2 diabetes Glucagon/GLP-1 co-agonists have superior metabolic benefits compared to monoagonists What is the key question? What are key determinants of plasma proglucagon (gcg) and is elevated plasma gcg a cause or consequence (or both) of type 2 diabetes? What are the new findings? Plasma levels of gcg are increased in type 2 diabetes, MASLD and obesity independently of each other Increased plasma gcg associates with higher risk of type 2 diabetes development Glucagon signalling associates with hepatic fat How might this impact on clinical practice in the foreseeable future? Biased glucagon receptor-regulating agents may be beneficial in the treatment of obesity and MASLD.